Bicara Therapeutics Inc. - 8-K Filing
Bicara Therapeutics reports Q3 2026 net loss of $71.2 million and announces substantial enrollment in FORTIFI-HN01 pivotal trial. (Items: 2.02 and in Exhibit 99)
Tickers: $BCAX
More Regulatory news
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing